PCSK1N and cystic kidney disease: In our analysis, we found that plasma PCSK1N was significantly elevated compared with renal cyst (FC = 19.6, p = 1.3*10−22) and S-AML (FC = 8.97, p = 2.36*10−5) but was reduced dramatically after everolimus treatment (FC of post vs. pre = 0.3, p = 1.29*10−8), which indicated that plasma PCSK1N may be a useful marker for TSC.